FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease

Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors

(2019) Li Zhu et al.   Journal for ImmunoTherapy of Cancer

Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer

(2018) Katherine A. Hoadley et al.   CELL

Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer

(2018) Marni B. Siegel et al.   JOURNAL OF CLINICAL INVESTIGATION

Immunological differences between primary and metastatic breast cancer

(2018) B Szekely et al.   ANNALS OF ONCOLOGY

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers

(2018) Pedram Razavi et al.   CANCER CELL

Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration

(2018) James M. McFarland et al.   Nature Communications

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

(2017) Hongchao Pan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases

(2017) Nolan Priedigkeit et al.   JAMA Oncology

Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients

(2016) Rin Ogiya et al.   CANCER SCIENCE

Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation

(2016) Thomas Welte et al.   NATURE CELL BIOLOGY

COSMIC: somatic cancer genetics at high-resolution

(2016) Simon A. Forbes et al.   NUCLEIC ACIDS RESEARCH

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

(2016) I. Tirosh et al.   SCIENCE

S100A8/A9 is associated with estrogen receptor loss in breast cancer

(2016) YI BAO et al.   Oncology Letters

Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis

(2016) Anna-Maria Georgoudaki et al.   Cell Reports

Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis

(2016) Celine Lefebvre et al.   PLOS MEDICINE

Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases

(2016) Bettina Sobottka et al.   OncoImmunology

Prognostic Value of Intrinsic Subtypes in Hormone Receptor–Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib

(2016) Aleix Prat et al.   JAMA Oncology

Development and verification of the PAM50-based Prosigna breast cancer gene signature assay

(2015) Brett Wallden et al.   BMC Medical Genomics

S100A9 expressed in ER−PgR− breast cancers induces inflammatory cytokines and is associated with an impaired overall survival

(2015) Caroline Bergenfelz et al.   BRITISH JOURNAL OF CANCER

A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer

(2015) Nicholas C. D'Amato et al.   CANCER RESEARCH

Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer

(2015) Giovanni Ciriello et al.   CELL

Inhibition of the autocrine IL-6–JAK2–STAT3–calprotectin axis as targeted therapy for HR−/HER2+breast cancers

(2015) Ruth Rodriguez-Barrueco et al.   GENES & DEVELOPMENT

Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms

(2015) Tamás Rőszer   MEDIATORS OF INFLAMMATION

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

(2015) M. Hagel et al.   Cancer Discovery

The Molecular Signatures Database Hallmark Gene Set Collection

(2015) Arthur Liberzon et al.   Cell Systems

Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study

(2014) Eduardo Martínez de Dueñas et al.   BREAST CANCER RESEARCH AND TREATMENT

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

(2014) A. Prat et al.   CLINICAL CANCER RESEARCH

An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer

(2014) Michael L Gatza et al.   NATURE GENETICS

Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

(2013) T. M. Zaid et al.   CLINICAL CANCER RESEARCH

Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts

(2013) Shunqiang Li et al.   Cell Reports

Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer

(2012) James S. Duncan et al.   CELL

Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models

(2012) P. J. Roberts et al.   CLINICAL CANCER RESEARCH

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models

(2012) Dorothy M. French et al.   PLoS One

Molecular signatures database (MSigDB) 3.0

(2011) A. Liberzon et al.   BIOINFORMATICS

Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures

(2011) Cheng Fan et al.   BMC Medical Genomics

Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse

(2011) J. Chuck Harrell et al.   BREAST CANCER RESEARCH AND TREATMENT

Treatment of HER2-positive breast cancer: current status and future perspectives

(2011) Carlos L. Arteaga et al.   Nature Reviews Clinical Oncology

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers

(2011) Craig H Mermel et al.   GENOME BIOLOGY

Metastatic Behavior of Breast Cancer Subtypes

(2010) Hagen Kennecke et al.   JOURNAL OF CLINICAL ONCOLOGY

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

(2009) Joel S. Parker et al.   JOURNAL OF CLINICAL ONCOLOGY

INPP5E mutations cause primary cilium signaling defects, ciliary instability and ciliopathies in human and mouse

(2009) Monique Jacoby et al.   NATURE GENETICS

Mammary development meets cancer genomics

(2009) Aleix Prat et al.   NATURE MEDICINE

Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers

(2009) Elgene Lim et al.   NATURE MEDICINE

The FGF family: biology, pathophysiology and therapy

(2009) Andrew Beenken et al.   NATURE REVIEWS DRUG DISCOVERY

The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells

(2009) A Roidl et al.   ONCOGENE

Subtypes of Breast Cancer Show Preferential Site of Relapse

(2008) M. Smid et al.   CANCER RESEARCH

Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases

(2008) P MEDINA et al.   CLINICAL THERAPEUTICS

Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer

(2008) D. Meijer et al.   ENDOCRINE-RELATED CANCER

Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention

(2008) Han Kiat Ho et al.   JOURNAL OF HEPATOLOGY

Kinase-Selective Enrichment Enables Quantitative Phosphoproteomics of the Kinome across the Cell Cycle

(2008) Henrik Daub et al.   MOLECULAR CELL